Please assess the completion status of the following clinical trial:

Trial Title: H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Human immunodeficiency virus (HIV) infection defined as documented by an enzyme-linked immunosorbent assay (ELISA) and confirmed with a Western blot at any time prior to study entry. Serum HIV-1 antigen, plasma HIV-1 ribonucleic acid (RNA), or any Food and Drug Administration (FDA) approved antibody test by a method other than ELISA is acceptable as an alternative confirmatory test.~* Males or non-pregnant females age 18-64, inclusive.~* Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral oophorectomy or hysterectomy or who are not postmenopausal for greater than or equal to 1 year) must agree to practice adequate contraception that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, barrier methods such as condoms, diaphragms, spermicides, intrauterine devices, Depo-Provera injections or Implanon implants for at least 30 days following the last vaccination.~* Are medically stable, as determined by the Investigator (based on review of health status, vital signs, medical history, and targeted physical examination. Vital signs must be within normal ranges prior to the first vaccination (heart rate 55-100, blood pressure systolic \<160, blood pressure diastolic \<90).~* Receipt of the 2009-2010 seasonal influenza vaccine at least two weeks prior to enrollment in this study.~* Intend to be available for follow-up visits and phone call access through 7 months following receipt of H1N1 vaccine.~* Are able to understand and comply with planned study procedures.~* Subject receiving regular medical follow-up care for HIV.~* Has a documented platelet count of \>50,000mm\^3 and an absolute neutrophil count (ANC) of \>500mm\^3 within the 3 months prior to study entry.~* Provide written informed consent prior to initiation of any study procedures.~Exclusion Criteria:~* Treatment for an opportunistic infection (OI) initiated within 2 weeks prior to enrollment, or have symptoms that have not stabilized.~* Have a known allergy to eggs or other components of the vaccine (including polymyxin, neomycin, and chicken protein).~* Women who are pregnant or breastfeeding.~* Have a positive urine or serum pregnancy test within 24 hours prior to vaccination.~* Use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months.~* Have a neoplastic disease that will be treated with chemotherapy or radiation, or a history of any hematologic malignancy.~* Have long term use of glucocorticoids including oral, parenteral or high-dose inhaled steroids. For oral or parenteral: prednisone or equivalent (greater than or equal to 2.0 mg/kg per day or greater than or equal to 20 mg total dose) for more than 2 consecutive weeks (or 2 weeks total) in the past 3 months. For inhaled steroids: \>800 mcg/day of beclomethasone dipropionate or equivalent within the preceding 6 months. (Nasal and topical steroids are allowed.)~* Have an uncontrolled major psychiatric diagnosis.~* Have a history of receiving immunoglobulin or other blood products within the 3 months prior to vaccination in this study.~* Received an experimental agent (vaccine, drug, biologic, device, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study (prior to the Day 201 follow-up call).~* Have received any live licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks prior to vaccination in this study or plan receipt of such vaccines within 21 days following the second vaccination.~* Have an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe, or would interfere with the evaluation of responses.~* Have a history of severe reactions following previous immunization with influenza virus vaccines.~* Have a moderate-severe acute illness, including an oral temperature greater than 100.4 degrees Fahrenheit, within 72 hours prior to vaccination. (This may result in a temporary delay of vaccination).~* Have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.~* Participated in a novel influenza 2009 H1N1 influenza vaccine study or have history of novel 2009 H1N1 influenza infection prior to enrollment.~* Have a history of alcohol or drug abuse in the last 3 months.~* Plan to travel outside of North America at any time between the first vaccination and 42 days following the first vaccination.~* Have a history of Guillain-Barré Syndrome.~* Have any condition that the investigator believes may interfere with successful completion of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Group 2, 30 mcg (Type: EXPERIMENTAL): CD4\<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
- Group 1, 15 mcg (Type: EXPERIMENTAL): CD4\<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete